Insider Selling: NovoCure (NASDAQ:NVCR) Chairman Sells $933,093.26 in Stock

NovoCure Limited (NASDAQ:NVCR) Chairman William Doyle sold 71,887 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the completion of the sale, the chairman directly owned 328,397 shares in the company, valued at approximately $4,262,593.06. The trade was a 17.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NovoCure Stock Performance

Shares of NVCR opened at $13.04 on Friday. NovoCure Limited has a 12-month low of $9.82 and a 12-month high of $21.55. The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.48 billion, a PE ratio of -10.69 and a beta of 0.71. The stock has a 50-day moving average price of $12.74 and a 200-day moving average price of $12.72.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The company had revenue of $174.35 million for the quarter, compared to analysts’ expectations of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. NovoCure’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.61) earnings per share. As a group, equities analysts forecast that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Kera Capital Partners Inc. boosted its stake in shares of NovoCure by 84.4% in the 4th quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider’s stock valued at $244,000 after purchasing an additional 9,015 shares in the last quarter. Corient Private Wealth LLC raised its position in NovoCure by 178.0% in the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after purchasing an additional 62,341 shares during the period. Mercer Global Advisors Inc. ADV raised its position in NovoCure by 14.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after purchasing an additional 4,124 shares during the period. Empowered Funds LLC bought a new stake in NovoCure in the fourth quarter worth $33,000. Finally, XTX Topco Ltd boosted its position in NovoCure by 159.2% during the fourth quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock valued at $760,000 after buying an additional 36,111 shares during the period. 84.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. HC Wainwright raised their price objective on shares of NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush restated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research report on Thursday, January 15th. Finally, Evercore set a $20.00 price target on NovoCure in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, NovoCure presently has a consensus rating of “Hold” and an average target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.